Mylan's Pursuit Of King Ends; King Says It's Ready To Go It Alone
This article was originally published in The Pink Sheet Daily
Executive Summary
"Significant enhancements" in commercial operations and business development organizations will allow King to grow as a standalone company, the firm says. Mylan and King announce termination of their proposed merger one day before the "walk-away" date.
You may also be interested in...
Mylan's Purchase Of Matrix Will Speed Launch Of ANDAs
Acquisition of the Indian drug maker would give Mylan an edge on generic R&D and production costs as well as access to European markets.
Mylan's Purchase Of Matrix Will Speed Launch Of ANDAs
Acquisition of the Indian drug maker would give Mylan an edge on generic R&D and production costs as well as access to European markets.
Savient Delays 10-Q Filing Due To Oxandrin Return Reserve Errors
The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.